DK3373931T3 - Heterocykliske forbindelser til behandling af sygdom - Google Patents
Heterocykliske forbindelser til behandling af sygdom Download PDFInfo
- Publication number
- DK3373931T3 DK3373931T3 DK16865156.0T DK16865156T DK3373931T3 DK 3373931 T3 DK3373931 T3 DK 3373931T3 DK 16865156 T DK16865156 T DK 16865156T DK 3373931 T3 DK3373931 T3 DK 3373931T3
- Authority
- DK
- Denmark
- Prior art keywords
- disease
- treatment
- heterocyclic compounds
- heterocyclic
- compounds
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562255041P | 2015-11-13 | 2015-11-13 | |
| PCT/US2016/061676 WO2017083756A1 (en) | 2015-11-13 | 2016-11-11 | Heterocyclic compounds for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3373931T3 true DK3373931T3 (da) | 2022-11-28 |
Family
ID=58696139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16865156.0T DK3373931T3 (da) | 2015-11-13 | 2016-11-11 | Heterocykliske forbindelser til behandling af sygdom |
Country Status (22)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3373931T (pt) | 2015-11-13 | 2022-12-06 | Oppilan Pharma Ltd | Compostos heterocíclicos para o tratamento de doenças |
| WO2018211323A1 (en) * | 2017-05-17 | 2018-11-22 | Oppilan Pharma Ltd. | Hetercyclic compounds for the treatment of disease |
| EP3625230A1 (en) * | 2017-05-17 | 2020-03-25 | Oppilan Pharma Ltd. | Prodrugs for the treatment of disease |
| GB201815018D0 (en) * | 2018-09-14 | 2018-10-31 | Univ Oxford Innovation Ltd | Enantiomeric compounds |
| JP2025524598A (ja) * | 2022-07-06 | 2025-07-30 | オピラン ファーマ リミテッド | Ｓ１ｐ受容体モジュレーターの結晶形態 |
| EP4649080A1 (en) * | 2023-01-13 | 2025-11-19 | Oppilan Pharma Ltd. | Preparation of an s1p receptor modulator |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4772597A (en) * | 1983-10-14 | 1988-09-20 | Pfizer Inc. | 2-azacycloalkylthiopenem derivatives |
| JP2007528872A (ja) * | 2003-10-01 | 2007-10-18 | メルク エンド カムパニー インコーポレーテッド | Ｓ１ｐ受容体アゴニストとしての３，５−アリール置換、ヘテロアリール置換またはシクロアルキル置換された１，２，４−オキサジアゾール化合物 |
| GB0511684D0 (en) * | 2005-06-08 | 2005-07-13 | Novartis Ag | Organic compounds |
| KR20080014009A (ko) * | 2005-06-08 | 2008-02-13 | 노파르티스 아게 | 폴리시클릭 옥사디아졸 또는 이속사졸, 및 이들의 ｓ１ｐ수용체 리간드로서의 용도 |
| RU2425832C2 (ru) * | 2006-04-03 | 2011-08-10 | Астеллас Фарма Инк. | Гетеросоединение |
| JP2010513283A (ja) | 2006-12-15 | 2010-04-30 | アボット・ラボラトリーズ | 新規なオキサジアゾール化合物 |
| US20110207704A1 (en) | 2006-12-15 | 2011-08-25 | Abbott Laboratories | Novel Oxadiazole Compounds |
| US20100160369A1 (en) * | 2008-12-04 | 2010-06-24 | Exelixis, Inc. | S1P1 Agonists and Methods of Making And Using |
| US20100249071A1 (en) | 2009-03-30 | 2010-09-30 | Exelixis, Inc. | Modulators of S1P and Methods of Making And Using |
| US9011494B2 (en) | 2009-09-24 | 2015-04-21 | Warsaw Orthopedic, Inc. | Composite vertebral rod system and methods of use |
| ES2665461T3 (es) | 2009-11-13 | 2018-04-25 | Celgene International Ii Sàrl | Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral |
| EP2595969B1 (en) * | 2010-07-20 | 2015-04-22 | Bristol-Myers Squibb Company | Substituted 3-phenyl-1,2,4-oxadiazole compounds |
| AU2012325916A1 (en) | 2011-10-20 | 2014-05-01 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| MX2016006936A (es) * | 2013-11-27 | 2016-10-05 | Genentech Inc | Benzamidas sustituidas y metodos para usarlas. |
| PT3373931T (pt) | 2015-11-13 | 2022-12-06 | Oppilan Pharma Ltd | Compostos heterocíclicos para o tratamento de doenças |
-
2016
- 2016-11-11 PT PT168651560T patent/PT3373931T/pt unknown
- 2016-11-11 HR HRP20221417TT patent/HRP20221417T1/hr unknown
- 2016-11-11 CA CA3005236A patent/CA3005236C/en active Active
- 2016-11-11 EP EP22195151.0A patent/EP4163281A1/en active Pending
- 2016-11-11 WO PCT/US2016/061676 patent/WO2017083756A1/en not_active Ceased
- 2016-11-11 AU AU2016353348A patent/AU2016353348A1/en not_active Abandoned
- 2016-11-11 IL IL259297A patent/IL259297B2/en unknown
- 2016-11-11 US US15/775,723 patent/US10683291B2/en active Active
- 2016-11-11 BR BR112018009745-4A patent/BR112018009745B1/pt active IP Right Grant
- 2016-11-11 RS RS20221070A patent/RS63837B1/sr unknown
- 2016-11-11 HU HUE16865156A patent/HUE060594T2/hu unknown
- 2016-11-11 ES ES16865156T patent/ES2932049T3/es active Active
- 2016-11-11 MX MX2018005987A patent/MX382092B/es unknown
- 2016-11-11 JP JP2018545102A patent/JP6933384B2/ja active Active
- 2016-11-11 LT LTEPPCT/US2016/061676T patent/LT3373931T/lt unknown
- 2016-11-11 EP EP16865156.0A patent/EP3373931B1/en active Active
- 2016-11-11 SM SM20230062T patent/SMT202300062T1/it unknown
- 2016-11-11 SI SI201631650T patent/SI3373931T1/sl unknown
- 2016-11-11 RU RU2018121416A patent/RU2727194C2/ru active
- 2016-11-11 DK DK16865156.0T patent/DK3373931T3/da active
- 2016-11-11 KR KR1020187016508A patent/KR102720397B1/ko active Active
- 2016-11-11 CN CN202111183182.7A patent/CN114149424B/zh active Active
- 2016-11-11 PL PL16865156.0T patent/PL3373931T3/pl unknown
- 2016-11-11 CN CN201680078856.8A patent/CN108463222B/zh active Active
-
2020
- 2020-05-01 US US16/865,212 patent/US20200325135A1/en not_active Abandoned
-
2021
- 2021-05-10 AU AU2021202945A patent/AU2021202945B2/en active Active
- 2021-08-11 JP JP2021131351A patent/JP7174963B2/ja active Active
-
2022
- 2022-03-18 US US17/698,991 patent/US20220227767A1/en not_active Abandoned
- 2022-10-28 JP JP2022173717A patent/JP7445325B2/ja active Active
-
2023
- 2023-06-29 US US18/344,594 patent/US20230339944A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285114A (en) | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | |
| DK3728271T3 (da) | Makrocykliske forbindelser til behandling af sygdomme | |
| IL259406B (en) | Heterocyclic compounds as immunomodulators | |
| DK3245206T3 (da) | Pyrazinforbindelser til behandling af infektionssygdomme | |
| DK3340981T3 (da) | Aryl, heteroaryl og heterocykliske forbindelser til behandling af medicinske forstyrrelser | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3143025T3 (da) | Forbindelser til behandling af spinal muskelatrofi | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK2988743T3 (da) | Heterocykliske forbindelser, der kan anvendes til behandling af sygdom | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3503890T3 (da) | Anvendelse af pridopidin til behandling af dystonier | |
| DK3498278T3 (da) | Forbindelser til behandling af sygdomme relateret til DUX4-ekspression | |
| DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3233813T3 (da) | Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser | |
| DK3210973T3 (da) | Heteroarylforbindelser til behandling af oftalmiske sygdomme | |
| DK3436074T3 (da) | Thiazolidforbindelser til behandling af virale infektioner | |
| DK3318115T3 (da) | Maskine til behandling af svinegylle | |
| DK3390407T3 (da) | Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser | |
| DK3578562T3 (da) | L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme | |
| DK3373931T3 (da) | Heterocykliske forbindelser til behandling af sygdom |